Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists and a growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban.
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding.
Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Cardiovascular risk factors are associated with venous thromboembolism and this association is clinically relevant with respect to individual screening, risk factor modification, and primary and secondary prevention of VTE.
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International…
- T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, W. Ageno
- Medicine, BiologyJournal of thrombosis and haemostasis : JTH
- 1 April 2013
Oral direct inhibitors of thrombin and factor Xa are now approved as anticoagulant drugs as pharmacokinetic and pharmacodynamic responses are reliably predicted in patients with adequate renal function who are not taking other interacting drugs.
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID‐19
Early reports suggest a high incidence of VTE in hospitalized COVID‐19 patients, particularly those with severe illness, that is similar to the high VTE rates observed in patients with other viral pneumonias, including severe acute respiratory syndrome (SARS) and Middle East respiratory Syndrome (MERS‐CoV).
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism.
The incidence of chronic thromboembolic pulmonary hypertension after the first episode of objectively confirmed pulmonary embolism was about 1%, and a diagnosis of CTPH was confirmed in two patients with idiopathic PE.
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
Increased D-dimer levels have gained particular attention as a predictor of the development of acute respiratory distress syndrome (ARDS), the need for admission to an intensive care unit (ICU) or death1-5, and many issues remain to be addressed.
Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome: Results of a Prospective Multicenter Study
Parenchymal hematoma, seen in about 3% of patients, is associated with an adverse outcome and was predicted by large lesions attributable to cardioembolism or other causes, high blood glucose, and treatment with thrombolysis.
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis.
It is concluded that OC users, and patients with factor V Leiden, the prothrombin G20 120A mutation, and hyperhomocysteinemia are at a significantly increased risk of CVT.